Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Galsulfase - BioMarin Pharmaceutical

Drug Profile

Galsulfase - BioMarin Pharmaceutical

Alternative Names: arylsulfatase B; Aryplase™; BM 102; Naglazyme; Recombinant human arylsulfatase B; recombinant human N-acetylgalactosamine-4-sulfatase; rhASB

Latest Information Update: 22 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMarin Pharmaceutical
  • Developer AnGes MG; BioMarin Pharmaceutical; Medison Pharma
  • Class Arylsulfatases; Recombinant proteins
  • Mechanism of Action N acetylgalactosamine 4 sulfatase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mucopolysaccharidosis VI

Most Recent Events

  • 22 Jul 2019 BioMarin Pharmaceutical completes a phase III open-label extension trial for Mucopolysaccharidosis VI in Ireland, before July 2019 (EudraCT2004-000642-21)
  • 25 Nov 2011 Launched for Mucopolysaccharidosis VI in Russia (IV)
  • 06 Apr 2011 Launched for Mucopolysaccharidosis VI in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top